The United Kingdom and the United States have agreed to a landmark trade agreement that will guarantee no levies on UK drug shipments entering the US market.
Agreement Details of the Accord
In exchange for the tariff guarantee, the UK has pledged to raise expenditure on drugs through the public health system. This pledge secures that tariffs on these vital exports will be held at nothing for a timeframe of the next three years.
This deal follows earlier statements to dramatically increase import taxes on patented drug imports, with figures floated as high as one hundred percent.
"This deal with the UK reinforces the global environment for new treatments and introduces long-overdue fairness to transatlantic pharmaceutical trade," an announcement said.
Trade Impact
Medicines are one of the UK's biggest export categories to the US, which is easily the largest buyer for leading British pharmaceutical firms.
Export figures show that in the 12 months leading up to September, the UK shipped medicines worth £11.1bn to the US. This value accounted for nearly one-fifth of all goods exports in that timeframe.
"This deal protects employment, increases capital expenditure and sets the stage for the UK to establish itself as a global hub for life sciences," the Business and Trade Secretary stated.
Detailed UK Commitments
The agreement includes several key commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new medicines to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a target to increase overall health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum drug companies must pay back to the NHS to control costs will be limited at fifteen percent. Last year, refunds topped twenty percent.
Industry Background
This agreement comes amid a ongoing row between the sector and the British authorities over drug pricing and regulatory access.
This friction were exacerbated by claims that American consumers were charged several times more for the same drugs than consumers in the UK and Europe.
In recent months, several significant manufacturing plans in the UK have been paused or cancelled, while substantial funding commitments have been directed toward American operations.
One official publicly accepted that the NHS must increase expenditure on treatments, noting that its expenditure on drugs had shrunk as a percentage of its resources over the last ten years.
